NEW YORK (GenomeWeb News) – Myriad Genetics today said that it has received approval to file an application transferring its shares from the Nasdaq stock exchange to the New York Stock Exchange.
The Salt Lake City-based developer of molecular diagnostics and therapeutics said that it expects to be trading on the NYSE Big Board in the second quarter of 2009. Once the transfer is complete, Myriad will trade under the symbol MGX.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.